COMBIVENT

LOE Approaching

albuterol sulfate; ipratropium bromide

NDAINHALATIONAEROSOL, METERED
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15

Mechanism of Action

RESPIMAT: COMBIVENT RESPIMAT is a combination of the anticholinergic ipratropium bromide and the beta 2 -adrenergic agonist albuterol sulfate. The mechanisms of action described below for the individual components apply to COMBIVENT RESPIMAT. The two classes of medications (an anticholinergic and a…

Clinical Trials (5)

NCT01969539Phase 4Terminated

Ventilator Adapters for Combivent Respimat

Started Oct 2013
11 enrolled
Pulmonary Disease, Chronic Obstructive
NCT01019694Phase 3Completed

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

Started Nov 2009
470 enrolled
Pulmonary Disease, Chronic Obstructive
NCT00818454Phase 2Completed

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

Started Dec 2008
226 enrolled
Asthma
NCT00400153Phase 3Completed

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

Started Nov 2006
1,480 enrolled
Pulmonary Disease, Chronic Obstructive
NCT00388882Phase 4Completed

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.

Started Oct 2006
327 enrolled
Pulmonary Disease, Chronic Obstructive